Target Audience
This activity was developed for pulmonologists, allergists, primary care physicians, nurses, nurse practitioners, and other clinicians involved in the management of severe asthma.
Learning Objectives
At the conclusion of this activity, participants should be better able to:
- Explain how phenotypic, endotypic, and other genetic characteristics factor into severe asthma
- Compare and contrast biological agents that are currently available or emerging in the treatment of severe asthma
- Identify patients who may benefit from the use of a biological agent for severe asthma
- Employ a stepwise approach to incorporating novel, personalized biologic-based treatment plans for severe asthma into the real-world clinical setting
Faculty
Jonathan Corren, MD
Clinical Associate Professor of Medicine and Pediatrics
Divisions of Clinical Immunology and Allergy
David Geffen School of Medicine at UCLA
Los Angeles, California
Michael Wechsler, MD
Professor of Medicine
Director, NJH Cohen Family Asthma Institute
Department of Medicine
National Jewish Health
Denver, Colorado
Accreditation
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of
1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The
Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for
Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned
ACPE Universal Program #. This program is designated for up to
1 contact hour (0.1 CEU) of continuing pharmacy education credit.
For Pharmacists —Transcript information will be available at www.mycpemonitor.net within 4 weeks.
The
Annenberg Center for Health Sciences is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207.
This program is designated for up to
1 contact hour. Program ID# 5664-EM.
The Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. A maximum of
1 contact hour
may be earned for successful completion of this activity.
Provider is approved by the California Board of Registered Nursing, Provider #13664, for
1 contact hour
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Disclosure Statement
It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.
The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:
Jonathan Corren, MD
- Research Support:
Genentech- clinical area: Asthma
AstraZeneca- clinical area: Asthma
Regeneron- clinical area: Asthma
Sanofi- clinical area: Asthma
Stallergenes Greer- clinical area: Allergic rhinitis
- Consultant:
Genentech- clinical area: Asthma
Novartis- clinical area: Asthma
Regeneron- clinical area: Asthma
Sanofi- clinical area: Asthma
- Speakers Bureau:
Genentech- clinical area: Asthma
Novartis- clinical area: Asthma
AstraZeneca- clinical area: Asthma
Michael Wechsler, MD
- Research Support:
AstraZeneca- clinical area: Asthma
Novartis- clinical area: Asthma
Sanofi- clinical area: Asthma
- Consultant:
AstraZeneca- clinical area: Asthma
Novartis- clinical area: Asthma
Teva- clinical area: Asthma
Boehringer Ingelheim- clinical area: Asthma
GlaxoSmithKline- clinical area: Asthma
Sanofi- clinical area: Asthma
Regeneron- clinical area: Asthma
The faculty for this activity has disclosed that there will be
discussion about the use of products for non-FDA approved applications.
Additional Content Planners
- Victoria Anderson (medical writer): No significant relationships to disclose
- Heather Jimenez, FNP (nurse reviewer): No significant relationships to disclose
- Kam Newman, MD (peer reviewer): No significant relationships to disclose
Annenberg Center for Health Sciences
Charles Willis, Director, Continuing Education, consults for Pfizer, Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
This activity is supported by educational grants from GlaxoSmithKline, AstraZeneca, Sanofi Genzyme and Regeneron Pharmaceuticals.
This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the material, reflecting on its implications in your practice, and completing the assessment component.
The estimated time to complete the activity is
1 hour.
This activity was originally released on
December 31, 2018 and is eligible for credit through
December 30, 2019.
Our Policy on Privacy
Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us, or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at http://www.annenberg.net/privacy-policy/
Contact Information
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
ce@annenberg.net
Phone: 760-773-4500
Fax: 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday